Curis, Inc. announced the appointment of Reinhard von Roemeling, M.D., as Senior Vice President, Clinical Development, and Christine Guertin as Vice President, Regulatory Affairs & Quality Assurance. Dr. von Roemeling has extensive global experience designing and advancing early- and late-stage clinical trials for oncology candidates. He joins the company from his role as Global Head of Research and Development at Huya Bioscience International. Previously, Dr. von Roemeling held various leadership roles in oncology research and clinical development at EMD-Serono, Daiichi Sankyo, Fresenius Group, Schering AG/Berlex, Boehringer Ingelheim, Sanofi and Sterling-Winthrop. Dr. von Roemeling has directed, co-directed and supported over 50 small molecule and biologics development programs. He holds an M.D. from Goethe University of Frankfurt. Ms. Guertin joins the company with over twenty years of experience in regulatory affairs in the biopharmaceutical industry. She previously served as Head of Regulatory Affairs at Synlogic, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.